CP-202 Ustekinumab treatment in refractory inflammatory bowel disease

• Published in: European journal of hospital pharmacy. Science and practice Vol. 24; no. Suppl 1; p. A90
• Main Authors: Afonso, L Senra, Fernández, M Oro, Sarría, C Garay, Gutiérrez, H Cristóbal, Vega, MA Martín, de Ilarduya Bolado, E Martínez, Gómez, N Lizama, Pérez, JF Mayorga, Uranga, A Illaro, Domínguez, M Valero
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.03.2017
• Subjects: Crohns disease; Cytokines; Inflammatory bowel disease; Monoclonal antibodies; Tumor necrosis factor-TNF

BackgroundUstekinumab is a human monoclonal antibody against interleukin 12 and interleukin 23. Its use in inflammatory bowel disease (IBD) is little known.PurposeTo evaluate the effectiveness and safety of ustekinumab in adults with moderate to severe IBD resistant to anti-tumour necrosis factor (T...